Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person UniProt:P16410 CTLA4
| Class:Id | ReferenceGeneProduct:53042 |
|---|---|
| _chainChangeLog | signal peptide:1-35 added on Fri February 6 2015;chain:36-223 added on Fri February 6 2015 |
| _displayName | UniProt:P16410 CTLA4 |
| _timestamp | 2026-02-20 22:42:14 |
| chain | signal peptide:1-35 chain:36-223 |
| checksum | 6F9466FB2E139A5A |
| comment | FUNCTION Inhibitory receptor acting as a major negative regulator of T-cell responses (PubMed:11279501, PubMed:11279502, PubMed:16551244, PubMed:1714933, PubMed:18641304, PubMed:28484017). Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28 (PubMed:11279501, PubMed:11279502, PubMed:16551244, PubMed:1714933, PubMed:28484017).SUBUNIT Homodimer; disulfide-linked (PubMed:11279501, PubMed:11279502, PubMed:21156796, PubMed:28484017, Ref.24). Interacts with ICOSLG (PubMed:28484017).INTERACTION Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalization.ALTERNATIVE PRODUCTS Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation.PTM N-glycosylation is important for dimerization.PTM Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.POLYMORPHISM Genetic variations in CTLA4 are associated with susceptibility to several autoimmune disorders (PubMed:10189842, PubMed:10924276, PubMed:12724780, PubMed:15138458, PubMed:15657618, PubMed:15688186, PubMed:18595775, PubMed:25213377, PubMed:25329329). They influence responsiveness to hepatitis B virus (HBV) infection [MIM:610424] (PubMed:15452244).DISEASE Disease susceptibility is associated with variants affecting the gene represented in this entry.DISEASE Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.DISEASE Disease susceptibility is associated with variants affecting the gene represented in this entry.DISEASE Disease susceptibility is associated with variants affecting the gene represented in this entry.DISEASE The disease is caused by variants affecting the gene represented in this entry.PHARMACEUTICAL Engineered fusion proteins consisting of the extracellular domain of CTLA4 and the IgG Fc region (Ctla4-Ig), inhibit T-cell-dependent antibody responses, and are used as immunosuppressive agents. They are soluble, have an enhanced affinity for B7 ligands and act as a competitive inhibitor of CD28.MISCELLANEOUS The therapeutic antibody Ipilimumab competes for the binding site of the endogenous ligands CD80/B7-1, CD86/B7-2 and ICOSLG.ONLINE INFORMATION CLTA-4 entry |
| description | recommendedName: Cytotoxic T-lymphocyte protein 4 alternativeName: Cytotoxic T-lymphocyte-associated antigen 4 shortName: CTLA-4 cdAntigenNameCD152/cdAntigenName |
| geneName | CTLA4 CD152 |
| identifier | P16410 |
| isSequenceChanged | FALSE |
| keyword | 3D-structure Adaptive immunity Alternative splicing Cell membrane Diabetes mellitus Disease variant Disulfide bond Glycoprotein Immunity Immunoglobulin domain Membrane Pharmaceutical Phosphoprotein Proteomics identification Reference proteome Signal Systemic lupus erythematosus Transmembrane Transmembrane helix |
| modified | [InstanceEdit:9836292] Weiser, Joel, 2023-05-25 [InstanceEdit:9852000] Weiser, Joel, 2023-11-03 [InstanceEdit:9917590] Weiser, Joel, 2024-08-09 [InstanceEdit:9926675] Weiser, Joel, 2024-11-03 [InstanceEdit:9983091] Weiser, Joel, 2026-02-20 |
| name | CTLA4 |
| referenceDatabase | [ReferenceDatabase:2] UniProt |
| referenceGene | [ReferenceDNASequence:8877409] ENSEMBL:ENSG00000163599 CTLA4 [Homo sapiens] |
| secondaryIdentifier | CTLA4_HUMAN A0N1S0 E9PDH0 O95653 Q0PP65 Q52MC1 Q53TD5 Q5S005 Q8WXJ1 Q96P43 Q9UKN9 |
| sequenceLength | 223 |
| species | [Species:48887] Homo sapiens |
| (isoformParent) | [ReferenceIsoform:8975945] UniProt:P16410-1 CTLA4 [Homo sapiens] [ReferenceIsoform:8975946] UniProt:P16410-2 CTLA4 [Homo sapiens] [ReferenceIsoform:8975947] UniProt:P16410-3 CTLA4 [Homo sapiens] [ReferenceIsoform:8975948] UniProt:P16410-4 CTLA4 [Homo sapiens] [ReferenceIsoform:8975949] UniProt:P16410-5 CTLA4 [Homo sapiens] |
| (referenceEntity) | [EntityWithAccessionedSequence:179764] CTLA4 [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:388754] p-Y201,Y218-CTLA4 [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:390311] CTLA4 [Golgi membrane] [Homo sapiens] [EntityWithAccessionedSequence:390318] CTLA4 [endosome] [Homo sapiens] |
| (referenceSequence) | [ModifiedResidue:388752] O4'-phospho-L-tyrosine at 218 [ModifiedResidue:388753] O4'-phospho-L-tyrosine at 201 |
| [Change default viewing format] | |
No pathways have been reviewed or authored by UniProt:P16410 CTLA4 (53042)
